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of hyperferritinemia in the oldest individual identiﬁed with the
R178G mutation can either be interpreted as incomplete pene-
trance or as evidence against R178G being a disease causing
mutation. This raises an important question: When do we con-
sider a genetic variant disease causing?
In the age of genome wide association studies and whole gen-
ome sequencing, this question becomes increasingly important.
The frequency of a sequence variant does not necessarily reﬂect
the functional importance because even in ferroportin related
iron overload, common polymorphisms in SLC40A1, such as
Q248H, have been reported as a strong risk factor for hyperferr-
itinemia [1]. On the other hand, V72F represents a rare sequence
variant that may still be of little functional consequence [2].
Taken together, a genetic variant is likely to be disease caus-
ing if the mutation segregates with the disease within a family
and is not present in an ethnically matched population. In silico
studies can provide further evidence for the functional conse-
quence of genetic variations, which – for R178G – supports
the notion that this mutation is disease causing [3]. Finally,
functional and structural studies of the mutant protein in cells
or knock-in animals have not been reported for R178G. Hence,
the question remains whether R178G is disease causing or not.
This uncertainty is paradigmatic for ferroportin disease and is
expected to increase, because it remains to be resolved how to
analyze millions of sequence variants detected by next
generation sequencing technology [4] that, at the threshold of
entering clinical practice, can be interpreted and functionally
analyzed.
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Letters to the Editor
732Distinct, alcohol-modulated effects of PNPLA3 genotype
on progression of chronic hepatitis CTo the Editor:
Recent large-scale genetic studies in patients with chronic
hepatitis C (CHC) provide evidence for a signiﬁcant role of host
genetic factors in its natural course [1], response to therapy [2],
and incidence of therapy-related adverse effects [3]. Recently, a
variant (rs738409 G>C) within the gene coding for patatin like
phospholipase domain containing-3 (PNPLA3) was found associ-
ated with liver fat content and progression of non-alcoholic fatty
liver disease (NAFLD) and alcoholic liver disease (ALD) [4,5].
PNPLA3 modulates storage of triglycerides in hepatocytes by a
yet unknown mechanism possibly related to lipid hydrolysis or
cross-talk with other mechanisms governing lipid storage with
consecutive ‘‘lipid trapping’’ in those patients carrying genotype
PNPLA3 rs738409 GG [6]. Although there is agreement on the
important functional role of viral epitopes in the evolution of ste-
atosis in CHC [7,8], host genetic factors, such as PNPLA3 variation,
could further modulate the accumulation of liver fat. In this issue
of the Journal of Hepatology and elsewhere, two independent
groups of researchers from distinct European regions demon-
strate a signiﬁcant association of PNPLA3 rs738409 G with ﬁbro-
sis, steatosis, and inﬂammation in patients with CHC [9,10]. Cai
et al. included 626 patients from the Swiss Hepatitis C Cohort
Study and found a signiﬁcant association of PNPLA3 rs738409
GG carriage with steatosis of any degree in genotype non-3Journal of Hepatology 2patients, whereas no impact of this variant on the stage of liver
ﬁbrosis was observed [9]. Regarding this lack of association, a
stratiﬁed analysis of rs738409 towards steatosis and ﬁbrosis in
obese and/or alcoholic CHC patients would be interesting,
because BMI and alcohol consumption were independently asso-
ciated with the degree of steatosis in this cohort.
We ourselves tested a possible association of PNPLA3
rs738409 with the severity of steatosis and ﬁbrosis in 605 previ-
ously untreated Caucasian patients with CHC from three German
University centres (Table 1). Assuming a recessive model control-
ling for sex, age, BMI, andviral genotype3, both thepresenceof ste-
atosis (grades 1–3 versus grade 0) and cirrhosis (METAVIR stage 4
versus stage <4) was signiﬁcantly associated with genotype
PNPLA3 rs738409 GG. Upon stratiﬁcation of alcohol intake into
abstainers (<30 g/day) and at-risk drinkers (>30 g/day), a distinct
risk pattern emerged: while genotype rs738409 GGwas primarily
relevant for steatosis in abstainers, its association with pre-treat-
ment ﬁbrosiswas restricted to at-risk drinkers. Our data are in line
with the large study from Valenti and coworkers from Italy [10],
who found a signiﬁcant association of genotype PNPLA3
rs738409 GG with steatosis and ﬁbrosis, no-response to antiviral
treatment, and the occurrence of hepatocellular carcinoma.
Together, data from these three independent studies lend
strong support for a signiﬁcant role of PNPLA3 rs738409 not only011 vol. 55 j 729–733




OR (95% CI) p OR (95% CI) p case/control
Total 5.53 (1.55-19.75) 0.009 1.86 (1.29-2.69) 0.001 273/169
Abstainersa 12.61 (1.48-107.7) 0.021 2.07 (1.25-3.44) 0.005 137/98
At risk drinkersb 2.61 (0.50-13.47) 0.253 1.74 (1.01-3.03) 0.049 136/71
Cirrhosis**
Total 2.76 (1.22-6.25) 0.015 1.47 (1.03-2.09) 0.033 115/490
Abstainersa 1.65 (0.54-5.03) 0.376 1.16 (0.73-1.84) 0.528 73/262
At risk drinkersb 4.77 (1.39-6.38) 0.013 2.03 (1.16-3.56) 0.014 42/228
Logistic regression analysis using SPSS (PASW statistics 18) was performed for the association between the PNPLA3 SNP and the presence of steatosis adjusting for age (45.8;
11.2), sex (47% females), BMI (25.0; 4.1), and viral genotype 3 (18.9%), and for the presence of cirrhosis adjusting for age (47.5; 11.6), sex (47% females), and BMI (25.1; 4.2)
under a recessive and additive model of inheritance. In the analysis for the presence of steatosis, cirrhotic patients were excluded.
⁄Steatosis (grades 1–3 versus grade 0).
⁄⁄Cirrhosis deﬁned as ﬁbrosis (stage 4 versus stage <4).
aAbstainers (<30 g alcohol per day).
bAt-risk drinker (>30 g alcohol per day); % values for frequencies; values for continuous variables expressed as means with standard deviation.
JOURNAL OF HEPATOLOGYin NAFLD and ALD, but also in CHC. Based on our dada, PNPLA3
rs738409 appears to convey distinct effects towards either mere
steatosis in non-drinkers, or progressive ﬁbrosis of CHC in those
who drink beyond amounts commonly considered as the thresh-
old for harmful drinking.
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